ACE inhibitors and ARBs have benefits beyond blood pressure control in people with kidney disease. These include slowing kidney disease progression, reducing albuminuria, and reducing cardiovascular risk. But data shows only a fraction of patients who are eligible for an ACEi or an ARB receive one. This module focuses on the evidence behind the role of ACEis and ARBs in patients living with kidney disease, and will also discuss how to safely initiate and monitor ACEis and ARBs in patients with kidney disease.
Emily Ashjian, PharmD, BCPS, BCACP, CDCES
Clinical Assistant Professor, University of Michigan College of Pharmacy
Dr. Emily Ashjian is a Clinical Assistant Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and a Clinical Pharmacy Specialist in Ambulatory Care at Michigan Medicine. Dr. Ashjian earned her Bachelor of Science in Molecular, Cellular and Developmental Biology at the University of Washington and her Doctor of Pharmacy from the University of North Carolina Eshelman School of Pharmacy. She completed her PGY1 Pharmacy Residency and PGY2 Ambulatory Care Pharmacy Residency at the University of Michigan serving as Chief Resident both years. Dr. Ashjian practices in an internal medicine clinic and a multidisciplinary chronic kidney disease clinic and serves as the PGY2 Ambulatory Care Residency Program Director at Michigan Medicine. Her primary areas of research interest include cardiovascular risk reduction, chronic kidney disease, diabetes, interprofessional education, and the scholarship of teaching and learning.
